How the 1968 Altman Z-Score and its modified Z'' variant work, why every Indian retail investor should run them as a first solvency filter, and how Titan Biotech (BSE: 524717) FY25 audited numbers illustrate a textbook safe-zone balance sheet.
The CFO/PAT ratio is the single fastest earnings-quality check any Indian value investor can run — and Titan Biotech FY25 audited numbers show what disciplined cash-backed profits actually look like.
Tversky & Kahneman's 1973 availability heuristic explains why Indian retail investors chase recent headlines. A detailed teaching post with an illustrative Titan Biotech FY25 case study on availability-resistant corporate behaviour.
Barber & Odean's Nobel-adjacent 2000 study, validated by SEBI's 2024 evidence that ~93% of Indian retail F&O traders lose money, explains the meta-bias that makes every other cognitive error worse — and the 8-question pre-trade checklist that disarms it.